Progyny (NASDAQ:PGNY) Director Kevin Gordon Sells 5,500 Shares of Stock

by · The Cerbat Gem

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) Director Kevin Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the completion of the sale, the director owned 9,318 shares in the company, valued at approximately $232,856.82. This represents a 37.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Progyny Price Performance

PGNY opened at $25.56 on Friday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75. The stock has a market cap of $2.00 billion, a P/E ratio of 33.19, a P/E/G ratio of 1.37 and a beta of 0.91. The stock’s 50 day moving average price is $19.83 and its 200 day moving average price is $22.25.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. During the same period last year, the firm earned $0.17 EPS. The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts anticipate that Progyny, Inc. will post 1.12 EPS for the current year.

Progyny declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. grew its stake in Progyny by 57.1% in the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after purchasing an additional 256,078 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after buying an additional 235,513 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of Progyny by 336.0% in the third quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock worth $3,655,000 after buying an additional 130,885 shares during the last quarter. Algert Global LLC lifted its position in shares of Progyny by 35.1% in the third quarter. Algert Global LLC now owns 595,805 shares of the company’s stock worth $12,822,000 after buying an additional 154,930 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after buying an additional 696,447 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several research analyst reports. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. Barclays raised their price objective on Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Finally, KeyCorp reduced their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.55.

Get Our Latest Report on Progyny

About Progyny

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Featured Articles